Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-effect and dosing frequency study of AMG 151 in type 2 diabetes mellitus
2012-001382-32Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing AMG 151 arm with Placebo arm (2 arms). Primary endpoint: Change in fasting plasma glucose from baseline to Day 28. Started Apr 2012; status: completed.
02
Drugs
arry-403
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-001382-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001382-32.